| 000 | 01251 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250514165320.0 | ||
| 264 | 0 | _c20040917 | |
| 008 | 200409s 0 0 eng d | ||
| 022 | _a1538-7933 | ||
| 024 | 7 |
_a10.1111/j.1538-7836.2004.00559.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aExaire, J E | |
| 245 | 0 | 0 |
_aShould glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? Yes. _h[electronic resource] |
| 260 |
_bJournal of thrombosis and haemostasis : JTH _cJan 2004 |
||
| 300 |
_a7-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAbciximab |
| 650 | 0 | 4 |
_aAngioplasty, Balloon, Coronary _xmethods |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin Fab Fragments _xadverse effects |
| 650 | 0 | 4 |
_aPlatelet Aggregation Inhibitors _xadverse effects |
| 650 | 0 | 4 |
_aPlatelet Glycoprotein GPIIb-IIIa Complex _xantagonists & inhibitors |
| 650 | 0 | 4 | _aSafety |
| 700 | 1 | _aLincoff, A M | |
| 773 | 0 |
_tJournal of thrombosis and haemostasis : JTH _gvol. 2 _gno. 1 _gp. 7-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1538-7836.2004.00559.x _zAvailable from publisher's website |
| 999 |
_c14446290 _d14446290 |
||